Acumen Pharmaceuticals Advances Sabirnetug for Alzheimer's, Reports Q3 2024 Financials
• Acumen Pharmaceuticals is progressing its Phase 2 ALTITUDE-AD trial of sabirnetug, an immunotherapy for Alzheimer's, with enrollment expected to complete in H1 2025.
• The company's Phase 1 trial showed sabirnetug was well-tolerated and reduced amyloid plaque load, supporting its continued development for early Alzheimer's disease.
• A collaboration with Halozyme, Inc. is underway to develop a subcutaneous formulation of sabirnetug, with Phase 1 PK comparison trial results anticipated in Q1 2025.
• Acumen's Q3 2024 report reveals increased R&D spending due to clinical trial advancements, with sufficient funds to operate into the first half of 2027.
© Copyright 2025. All Rights Reserved by MedPath